Peptide Glow Journal

Microneedling and Copper Peptides: The One Experiment That Measured It

Microneedling solves the penetration problem copper peptides have — 134 nanomoles crossed treated skin against almost none through intact skin. What that does and does not prove.

Fiona G · Published 2026-09-08

Every page this publication has written about copper peptides runs into the same wall: the molecule has to get into the skin, and the evidence that it does is thin. Microneedling is the one intervention that answers that objection directly — it makes temporary channels through the barrier. So we went looking for what has actually been measured. There is one experiment. Its numbers are striking, and the clinical trial that should have followed it has never been run.

The census

Search (PubMed, 2026-09-08) Records
Microneedling / microneedles, any 6,750
Microneedling, randomized controlled trials 137
Microneedling + any peptide 341
Microneedling + any peptide, randomized controlled trials 2 (1 after removing a dengue vaccine study)
Microneedling + copper peptide or GHK 4
Microneedling + copper peptide, clinical trials of the combination 0

The shape is worth pausing on. This is not an under-studied procedure — 137 randomized trials is a substantial literature, and microneedling has been tested against scarring, pigmentation and photoaging repeatedly. The gap is specific: the procedure is studied, the ingredient is studied, and the combination that consumers are sold has been measured once, in a laboratory, eleven years ago.

The one experiment, and its numbers

Researchers at the National University of Singapore used a polymeric microneedle array to pre-treat skin, then measured how much GHK-Cu crossed. Two in vitro skin models were used; microconduits were characterised by histology and confocal laser scanning microscopy; safety was assessed in cellular and porcine models (Li et al., Pharm Res 2015).

Over nine hours:

Peptide permeated Copper permeated
Microneedle-treated human skin 134 ± 12 nmol 705 ± 84 nmol
Intact human skin almost none almost none

That is the cleanest answer anyone has produced to the question that hangs over the whole copper peptide category. Applied to unbroken skin, GHK-Cu essentially does not cross. Applied to skin with microconduits in it, it crosses in measurable quantity.

Two further findings from the same paper matter as much as the headline.

Delivery scaled with force. The depth and the percentage of needles that penetrated correlated with the application force, and that in turn determined how much peptide crossed. Dose is therefore a function of technique — a fact with no equivalent in ordinary skincare, where the amount applied is the amount applied.

The copper outran the peptide roughly five to one. If the complex travelled through the channels intact, copper and peptide would arrive in equal molar amounts. They did not: 705 nanomoles of copper against 134 of peptide. The complex is partly dissociating, and free copper is crossing in excess of the peptide carrying it. Since the argument for copper peptides over copper salts rests on the metal staying chelated, this is a meaningful observation, and we have not seen it made anywhere in consumer coverage of the combination.

The study reported no obvious signs of skin irritation with GHK-Cu after microneedle pretreatment, in cellular and porcine models.

What the review literature says about the general case

The 2015 result is not an outlier. A 2022 review in the International Journal of Cosmetic Science examined skin permeability across anti-wrinkle peptides and reached a blunt conclusion: most are not appropriate candidates for skin permeation, and enhancement methods are essential rather than optional. It lists what has been tried — chemical modification with hydrophobic moieties or cell-penetrating peptides, metal complexation, chemical permeation enhancers, iontophoresis, microneedles, nanocarrier encapsulation — and names GHK among the peptides whose permeability has been successfully increased (Mortazavi & Moghimi, Int J Cosmet Sci 2022).

The review's framing of the problem is the sentence worth keeping: cellular studies indicate these peptides are effective, but without the ability to permeate skin sufficiently, that effectiveness is useless. Our copper peptides page carries the same caveat from the 2025 GHK review that questions how much crosses intact skin at all.

What has not been tested

No clinical trial of copper peptides after microneedling exists. Four records join the two subjects, and they are the 2015 delivery experiment, two reviews of GHK-Cu that mention microneedles among delivery options, and a paper on ionic liquid microemulsions for topical peptide delivery. None enrolled people receiving the combination and measured a cosmetic outcome.

The single randomized trial of a topical peptide following a microneedling-type procedure used a different peptide entirely: a split-face, double-blind study of an angiopoietin-1 derived peptide after fractional radiofrequency microneedling. It says nothing about copper.

So the honest position is a split one. The delivery question has an answer and it is favourable. The efficacy question — whether more GHK-Cu reaching the dermis produces a better visible result than less — has never been asked in a trial.

The safety question the delivery result creates

Better penetration is not straightforwardly good news, and this is where the finding should make a reader more careful rather than less.

A cosmetic serum is formulated, preserved and safety-assessed on the assumption that it sits on intact skin. Microneedling voids that assumption for everything in the bottle at once — preservatives, fragrance, other actives, and whatever else the formula carries travel through the same channels the peptide does. Microneedling has its own documented complication literature; a PubMed search on 2026-09-08 returned 341 records touching granuloma, infection, adverse events or complications from the procedure.

Add the dissociation finding — free copper crossing at five times the peptide's molar quantity — and the combination raises a question that intact-skin use does not: what is being delivered is not only more of the ingredient, it is partly a different chemical entity from the one on the label.

None of that establishes harm. It establishes that a laboratory permeation result is not a safety assessment for a procedure done at home, and that the study reporting it used porcine and cellular models rather than human volunteers.

What would settle it

A split-face randomized trial: microneedling on both sides, GHK-Cu serum on one and its vehicle on the other, with wrinkle and pigmentation endpoints and adverse events recorded, at a documented needle depth. The delivery groundwork was published in 2015 and the design is unremarkable. Eleven years on, nobody has run it.

More from this publication: the ingredient's full evidence record in copper peptides, the layering evidence in what not to mix with copper peptides, the molecular-weight arithmetic in peptides for skin, and the research end of the category in the glow stack. Our testing notes explain how we handle claims that outrun their evidence.

Sources

  • PubMed searches run 2026-09-08 via NCBI E-utilities esearch, title/abstract terms as described in the table; publication type filter "randomized controlled trial"[pt]. All four microneedling-and-copper-peptide records and both microneedling-and-peptide trial records were retrieved and read; the dengue vaccine study was excluded on inspection. PubMed.
  • Li H, Low YS, Chong HP, Zin MT, Lee CY, Li B, Leolukman M, Kang L. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharm Res 2015;32(8):2678-89. PubMed 25690343. In vitro human skin models; safety assessed in cellular and porcine models.
  • Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci 2022;44(2):232-248. PubMed 35302659.
  • A Randomized, Double-Blind, Split-Face, Clinical Trial of Angiopoietin-1 Derived Peptide Topical Following Fractional Radiofrequency Microneedling. J Drugs Dermatol 2025. PubMed 40911750.
  • Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts 2025. PubMed 39963574.

Published by Peptide Glow Journal Editorial. No product is ranked, scored or affiliate-linked on this page.

Frequently asked questions

Does microneedling help copper peptides absorb?

In the one experiment that measured it, dramatically. Over nine hours, 134 nanomoles of GHK-Cu and 705 nanomoles of copper crossed microneedle-treated human skin, while almost nothing crossed intact skin. That is the clearest available answer to the penetration question that hangs over every copper peptide product. The important qualifications are that the work used laboratory skin models rather than living volunteers, and that no clinical trial has since tested whether the extra delivery produces a better cosmetic result.

Should you use copper peptides after microneedling?

This publication does not issue routines, and here the evidence genuinely cannot support one. No randomized trial has tested copper peptides applied after microneedling — the entire literature joining the two is four records, none of them a clinical trial of the combination. What is established is that microneedling makes the skin far more permeable to GHK-Cu, which raises rather than settles the safety question: a barrier deliberately breached admits whatever else is in the formula. Anything applied to broken skin is a clinical decision, not a cosmetic one.

How much copper peptide gets through normal skin?

Close to nothing, on the one direct measurement available. The 2015 study reports that almost no peptide and almost no copper permeated intact human skin over nine hours, against 134 and 705 nanomoles respectively through microneedle-treated skin. That result is consistent with the molecular arithmetic — copper tripeptide-1 is water-loving and charged, which is the opposite of what crosses a lipid barrier — and it is why formulators reach for palmitoylation, carriers and delivery devices.

Is microneedling with copper peptides safe?

Nobody has run the trial that would answer it. The 2015 laboratory work reported no obvious signs of skin irritation in cellular and porcine models after microneedle-assisted GHK-Cu delivery, which is a safety signal from a laboratory rather than from people. Two facts frame the question honestly: microneedling itself has a documented complication literature covering infection and granuloma formation, and a product formulated to sit on intact skin has not been assessed for what happens when it is delivered past the barrier. Preservatives, fragrances and other actives cross the same channels.

Why does copper cross faster than the peptide?

That is the most interesting detail in the experiment and it is rarely noted. Copper permeated at roughly five times the molar quantity of the peptide — 705 nanomoles against 134. If GHK-Cu moved through the channels intact, the two would arrive in equal molar amounts. They did not, which indicates the complex partly dissociates, with free copper crossing in excess. The whole premise of a copper peptide is that the metal stays chelated, and this measurement suggests that premise weakens once the barrier is opened.

Are there trials of peptides applied after microneedling?

One, and it is not about copper. A randomized, double-blind, split-face trial tested a topical angiopoietin-1 derived peptide following fractional radiofrequency microneedling. A search for randomized trials joining microneedling with peptides returns two records, but the second is a dengue vaccine study caught because the vaccine is peptide-based — the kind of false positive that makes a raw count untrustworthy until each record is read.

Does the needle depth matter?

In the one study measuring delivery, yes and measurably so: penetration depth and the percentage of needles that penetrated both correlated with the force applied, and that in turn determined how much GHK-Cu crossed. The practical consequence is that dose is a function of technique. No device setting or protocol has been standardised against a delivery measurement, so two people using the same serum after the same nominal procedure are not receiving the same amount.